Guggenheim Remains Bullish Ahead of Teva Pharma's (TEVA) AGN Deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Teva to Report First Quarter 2016 Financial Results on May 9, 2016
April 18, 2016 8:31 AM EDTJERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that it will release its first quarter 2016 financial results on Monday, May 9, 2016 at 7:00 a.m. ET.
Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its first quarter 2016 results and overall business environment. A Question & Answer session will follow this discussion.
In order to participate, please dial the following numbers (at least 10 minutes before the scheduled start time): United States 1-866-254-0808; Canada 1-866-607-2172 or... More
Teva Presents New Data for SD-809 in Huntington Disease at 68th American Academy of Neurology (AAN) Annual Meeting in Vancouver, B.C.
April 18, 2016 8:01 AM EDTFirst-HD Study shows improvements in Total Motor Score and Swallowing Function in Huntington disease patients treated with SD-809
JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in Huntington Disease (First-HD) study evaluating the efficacy, safety and tolerability of SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). The data will be featured during two... More
